Novartis

Fabrikstrasse 2, 4056 Basel
Novartis   link
Location: Basel
Discipline: Pharmacology
Related:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

#display_name

Pharmacology - Health - Jan 20
Patients & Caregivers Healthcare Professionals Society & ESG - Mayzent (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe 1 -   Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did not ha
Pharmacology - Health - Jan 9

Patients & Caregivers Healthcare Professionals Society & ESG - Data show ligelizumab binds to immunoglobulin E (IgE), a key driver of chronic spontaneous urticaria (CSU), with significantly higher affinity than current standard of care Xolair (omalizumab) 1 -   The study published suggests

Pharmacology - Jan 6

Patients & Caregivers Healthcare Professionals Society & ESG - Basel, January 6, 2020 - Novartis AG (NYSE: NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger Corporation ("Purchaser"), f

Pharmacology - Health - Dec 13, 2019

Patients & Caregivers Healthcare Professionals Society & ESG In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one 1 -   In a pre-specified secondary endpoint, fewer patients had intra-retinal fluid and/or sub-retina

Pharmacology - Health - Dec 9, 2019

Patients & Caregivers Healthcare Professionals Society & ESG Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients 1-3 -   Fewer known CAR-T cell therapy adverse events for patients wit

Pharmacology - Health - Jan 6

Patients & Caregivers Healthcare Professionals Society & ESG - Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL cholesterol (LDL-C) goal and remain

Pharmacology - Health - Dec 16, 2019

Patients & Caregivers Healthcare Professionals Society & ESG Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication -   Fevipiprant was well tolerated with adverse events balanced across treatment groups - Basel, Switzerland,

Health - Pharmacology - Dec 11, 2019

Patients & Caregivers Healthcare Professionals Society & ESG MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results for Kisqali plus fulvestrant, reducing the risk of death by almost 30% -   Overall survival benefi

Health - Pharmacology - Dec 9, 2019

Patients & Caregivers Healthcare Professionals Society & ESG - Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell disease and a pattern of not seeking care despite potentially life-threatening symptoms 1 -   Patien



Job Offers

» Job Offer: Novartis

Last job offers



website preview

Link

Medicine and Life Sciences